Trial Profile
A HR-pQCT Study in Postmenopausal Women Previously Treated With Denosumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Bone resorption; Fracture; Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Amgen
- 17 Feb 2017 New trial record